DRB18
DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity[1].
Product Specifications
CAS Number
2863686-81-9
UNSPSC
12352005
Target
GLUT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/drb18.html
Concentration
10mM
Purity
99.58
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
ClC1=CC(NCC2=CC(O)=C(C)C=C2)=C(NCC3=CC=C(C)C(O)=C3)C=C1
Molecular Formula
C22H23ClN2O2
Molecular Weight
382.88
References & Citations
[1]Shriwas P, Roberts D, Li Y, et al. A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism. Cancer Metab. 2021;9 (1) :14. Published 2021 Mar 26.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15355819 1 Vial
Lentiviral human ESRP2 sgRNA gene knockout kit - Lentiviral human ESRP2 sgRNA gene knockout kit (plasmid)
Sign In for Pricing
View Details